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Abstract: Zinc could have a protective role against type 2 diabetes mellitus (T2DM). This systematic
review and meta-analysis aimed to evaluate the association between dietary, supplementary, and
total zinc intake, as well as serum/plasma and whole blood zinc concentration, and risk of T2DM.
Observational studies, conducted on cases of incident diabetes or T2DM patients and healthy
subjects that reported a measure of association between zinc exposure and T2DM, were selected.
Random effects meta-analyses were applied to obtain combined results. Stratified meta-analyses and
meta-regressions were executed to assess sources of heterogeneity, as well as the impact of covariates
on the findings. From 12,136 publications, 16 studies were selected. The odds ratio (OR) for T2DM
comparing the highest versus lowest zinc intake from diet was 0.87 (95% CI: 0.78–0.98). Nevertheless,
no association between supplementary or total zinc intake from both diet and supplementation, and
T2DM was observed. A direct relationship was found between serum/plasma zinc levels and T2DM
(OR = 1.64, 95% CI: 1.25–2.14). A moderately high dietary zinc intake, in relation to the Dietary
Reference Intake, could reduce by 13% the risk of T2DM, and up to 41% in rural areas. Conversely,
elevated serum/plasma zinc concentration was associated with an increased risk of T2DM by 64%,
suggesting disturbances in zinc homeostasis.
Keywords: zinc intake; zinc status; trace elements; type 2 diabetes mellitus; systematic review;
meta-analysis; epidemiology
1. Introduction
Diabetes mellitus is a major public health challenge worldwide, and is a key contributor to
morbidity and mortality. In 2016, diabetes mellitus was listed as the seventh leading cause of death
globally [1]. According to the International Diabetes Federation (IDF) Diabetes ATLAS, the global
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prevalence of diabetes among individuals aged 20–79 years in 2017 was 8.8% (95% confidence interval
(CI): 7.2–11.3), i.e., 424.9 million people, with a total healthcare expenditure estimated at just under USD
727 billion [2]. The number of people suffering from diabetes is expected to increase to 628.6 million in
2045, a prevalence of over 9.9% (95% CI: 7.5–12.7). Around 90% of cases of diabetes are type 2 diabetes
(T2DM) [2]. This disease results from the body’s ineffective use of insulin [1], and is the result of the
interaction of multiple genetic and environmental factors [3].
The role of zinc in the etiology of T2DM has been widely reported in recent decades. Longitudinal
large prospective cohort studies, such as the Nurses’ Health Study (NHS) cohort [4] in the USA; the
Australian Longitudinal Study on Women’s Health cohort study [5]; the Malmö Diet and Cancer Study
cohort [6] in Sweden; and the Japan Collaborative Cohort study [7], among others, have investigated
the effect of dietary, supplementary, and/or total zinc intake on the risk of developing T2DM. The
NHS cohort was the first to prospectively analyze these relationships, and it reported that the higher
the total and/or dietary zinc intake, the lower the risk of T2DM over subsequent years [4]. Although
a non-significant association was observed between supplementary zinc intake and risk of T2DM
in the overall sample, an inverse relationship was seen in those participants with low dietary zinc
intake [4]. There is currently no evidence that supports the use of zinc supplements in the prevention
of T2DM [8]. Nevertheless, a recent clinical trial based on zinc supplementation has found a reduction
in the progression to diabetes in prediabetic subjects [9]. Some subsequent prospective cohort studies,
however, have failed to confirm some of the results reported in the NHS cohort [6,10–12]. A systematic
review of prospective studies that aimed to examine the role of zinc intake and status on the risk of
T2DM revealed inconsistencies between studies, and suggested the possible influence of confounding
factors on these relationships [13].
Similarly, findings on the relationship between serum/plasma zinc concentration and T2DM
are contradictory [14–16]. The prospective Kuopio Ischaemic Heart Disease Risk Factor (KIHD)
cohort study of 2220 Finnish men followed over twenty years showed that higher serum zinc
levels were associated with an increased risk of T2DM [14]. Conversely, a cross-sectional study of
128 Russian postmenopausal women found an inverse relationship between serum zinc and T2DM [17].
The relationship between whole blood zinc concentration and T2DM has been investigated by two
studies carried out within the same population-based Nord-Trøndelag Health Study (HUNT3), but
their results were inconclusive [18,19]. The study conducted on newly diagnosed T2DM patients
found a positive association between whole blood zinc concentration and T2DM [18], while the study
performed in previously diagnosed T2DM patients showed no association [19]. In our previous
systematic review and meta-analysis, which aimed to compare whole blood zinc concentration between
T2DM patients and non-diabetic subjects, we observed a lower whole blood zinc concentration in
T2DM patients [20]. It should be noted that diabetic subjects had, at least, 10.2 ± 8.6 years of duration
of diabetes. Therefore, the duration of diabetes may have an impact on this association, and it is
important to clarify this relationship.
The mechanism whereby zinc could have an impact on the risk of T2DM has not been completely
elucidated, however zinc is an essential trace element that is involved in the physiology of carbohydrate
metabolism in many ways. Zinc participates in the adequate insulin synthesis, storage, crystallization,
and secretion in the pancreatic β-cell, as well as action and translocation of insulin into the
cells [21–24]. In addition, zinc seems to play a role in insulin sensitivity through the activation
of the phosphoinositol-3-kinase/protein kinase B cascade [25]. Due to its insulin–mimetic action, zinc
also stimulates glucose uptake in insulin-dependent tissues [26]. Moreover, zinc is implicated in the
suppression of proinflammatory cytokines, such as interleukin-1β [27] and nuclear factor kβ [28],
avoiding β-cells’ death and protecting insulin. All of these functions of zinc could support its potential
protective role against diabetes mellitus.
Much remains uncertain concerning the effect of zinc on the risk of developing T2DM. Therefore,
the purpose of this comprehensive systematic review and meta-analysis of observational studies was to
evaluate the association between dietary, supplementary, and total zinc intake, as well as serum/plasma
Nutrients 2019, 11, 1027 3 of 26
zinc and whole blood concentration and risk of T2DM in the adult population. A secondary objective
was to examine potential confounding factors that may impact on these relationships.
2. Materials and Methods
The protocol for this systematic review and meta-analysis of observational studies was registered
in PROSPERO (2015: CRD42015020178) and can be accessed here: (http://www.crd.york.ac.uk/
PROSPERO/display_record.php?ID=CRD42015020178). The study was conducted in accordance
with the Meta-Analyses of Observational Studies in Epidemiology (MOOSE) criteria statement [29].
The MOOSE checklist is shown in Supplementary Materials Table S1.
2.1. Search Strategy
This systematic review and meta-analysis were carried out by six investigators within the
framework of the EURopean micronutrient RECommendations Aligned (EURRECA) Network of
Excellence, one aim of which was to undertake a series of systematic search for studies assessing the
effect of zinc on different health outcomes. A comprehensive search was developed in MEDLINE
(Ovid), Embase (Ovid), and The Cochrane Library (CENTRAL) up to January 2019, using search
terms for (“study designs in humans”) AND (Zinc) AND (intake OR status). Additional articles were
identified through manual searching and citation tracking (Figure 1).
12.135 Records identified through 
MEDLINE (Ovid), Embase (Ovid) 
and The Cochrane Library 
(CENTRAL) 
 
93 Full-text manuscripts excluded: 
15 Without zinc exposure 
3 Without T2DM 
3 Diabetes other than T2DM 
11 Non-observational design 
61 Without measure of association 
 
105 Potentially relevant manuscripts 
identified for further full-text review 
 
12.030 Records excluded based on titles and 
abstracts: 
1648 Children 
440 Without zinc exposure 
5747 Without T2DM 
52 Diabetes other than T2DM 
797 Non-observational design 
676 Without measure of association 
2670 Duplicates 
 
16 Manuscripts included in the 
meta-analyses 
4 Manuscripts retrieved from manual searching 
Figure 1. Flowchart of the selection process.
2.2. Study Eligibility Criteria
Studies were selected according to the following inclusion criteria: (1) studies of observational
design, including prospective cohort, case-control, and cross-sectional; (2) studies conducted on
human adults, with type 2 diabetes mellitus (T2DM) or cases of incident diabetes and healthy control
individuals or controls of non-incident diabetes; (3) publications reported in English, Spanish or other
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European languages; (4) studies that reported a measure of association, such as relative risk (RR),
odds ratio (OD) or hazard ratio (HR), between dietary, supplementary, and/or total zinc intake and/or
serum/plasma and/or whole blood zinc concentration and T2DM, through a multivariable adjusted
analysis that compared the highest quantile of zinc exposure versus the lowest. Studies that compared
user versus non-user of zinc supplements in relation to T2DM were also selected. Other kinds of
observational study designs, such as case reports, case series or ecological studies; reviews; and
experimental or quasi-experimental studies, as well as those with participants diagnosed with diabetes
mellitus other than T2DM, were excluded.
2.3. Study Selection
Titles and abstracts of studies identified through the literature search were independently screened
for eligibility. Subsequently, the full text of relevant studies was retrieved and examined further against
the inclusion and exclusion criteria. Reasons for excluding studies were recorded. The selection
process was independently completed by members of the research team (JCFC, MWM, VHM, CD,
and NL). A 10% sample was cross-checked by another investigator (MWM) to ensure consistency
between reviewers, and any discrepancy or disagreement was resolved by discussion until consensus
was reached among the reviewers.
2.4. Data Extraction and Study Quality Assessment
One reviewer (JCFC) carried out the data extraction process using a data-extraction spreadsheet.
Two other reviewers (VHM and NL) independently screened the accuracy of the extracted data.
In order to avoid the inclusion of duplicate data in the meta-analyses, some strategies were applied:
first, the name of the project was recorded for all studies that met the inclusion criteria, as well as the
geographic location where the studies had been conducted; second, the lists of authors were compared
among them. Complementary data from the same project was included for a qualitative summary.
From each manuscript selected for inclusion, the following data were extracted into an excel
spreadsheet: study identification (first author’s name, year of publication, and name of the project),
study characteristics (study design, period of follow-up, measure of association, adjustment variables,
quality score, country, geographic regions, geographic area, sample base, matched design, sample size
for each group and total, zinc assessment method, zinc quantiles adjusted for energy, ascertainment of
T2DM, percentage of T2DM subjects, effect size, and 95% confidence interval (CI) for the most adjusted
model), and study population (age, gender, ethnicity, area of residence—dietary, supplementary and
total zinc intake, as well as serum, plasma, and whole blood zinc concentration—BMI, fasting glucose
levels, stage of diabetes). To incorporate relevant data in forms other than the mean and standard
deviation, such as median and the interquartile range, estimation methods proposed by Wan et al., [24]
were applied, which are valid for both normal and skewed data. When covariates of interest were
expressed as a range, the midpoint of the range was assumed. If any of the data were missing, the
authors were contacted for additional data.
The quality of studies selected was evaluated by one research investigator (JCFC) using the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement [25].
The STROBE checklist is shown in Supplementary Materials Table S2. The quality score was used to
assess its possible influence on results.
2.5. Statistical Analysis
Meta-analyses comparing the highest versus the lowest quantile of exposure to zinc intake and/or
status were performed when at least two studies with a common exposure in relation to T2DM were
available. For all meta-analyses, effect size and 95% CIs were log-transformed. Estimated standard
errors were calculated from log 95% CIs by subtracting the lower bound of the CI from the upper
bound and subsequently dividing by two times 1.96. The method of a random-effects model and
the generic inverse variance method were used to calculate the pooled effect sizes, reported as OR
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and 95% CI. Relative risks and hazard ratios were deemed equivalent to ORs [30]. The most adjusted
model of the multivariable analysis in the selected studies was used to estimate the effect size in all
meta-analyses. Forest plots were created to visualize individual and global estimates. As the studies
included in the meta-analysis on supplementary zinc intake and T2DM reported exposure either in
quantiles or as dichotomous variable (user versus no user), a stratified meta-analysis was performed
based on these criteria.
Univariate and multivariate meta-regressions with Knapp–Hartung modification [31] were
conducted to examine the potential impact of certain covariates on effect size. To display relevant
results of a single continuous covariate in univariate meta-regressions, bubble plots were created.
This graph represents the fitted regression line together with circles representing the estimates from
each study, sized according to the precision of each estimate (the inverse of its within-study variance).
Multivariate meta-regressions models were executed adding the covariate with the strongest association
in univariate analysis first and then adding the next one in turn. Covariates showing collinearity were
removed from the final multivariate model. Finally, a meta-regression equation was generated using
the intercept (a), as well as the regression coefficient (b) of a specific covariate, to know how the effect
size (OR for T2DM) changes with a unit increase in the exploratory covariate (Ln (ORT2DM) = (a) + b ×
(covariate)).
Heterogeneity was assessed by the Cochran Q-statistic and the I2 statistic to quantify the
percentage of variation attributable to between-study heterogeneity [32]. I2 values of 25%, 50%, and
75% were considered as low, medium, and high heterogeneity, respectively [33,34]. Potential sources
of heterogeneity were explored through stratified analyses and univariate meta-regressions, even if an
initial heterogeneity was non-significant [35], using different variables. Thus, categorical variables were:
study design, study design and area of residence, measures of association, quality score, geographic
regions, location, sample base, matched design, sample size, zinc intake assessment method, zinc
serum/plasma assessment method, ascertainment of T2DM, diagnostic pattern, percentage of T2DM,
gender, ethnicity, area of residence, group with higher serum/plasma zinc levels, zinc quantiles adjusted
for energy. In addition, continuous variables were also used, such as sample size for each group and
total, period of follow-up (years), quality score (%), percentage of T2DM subjects (%), age in cases
and controls (years), age difference and ratio between cases and controls (years), serum/plasma zinc
levels in cases and controls (µg/dL), serum/plasma zinc difference and ratio between cases and controls
(µg/dL), BMI in cases and controls (kg/m2), BMI difference and ratio between cases and controls (kg/m2),
fasting glucose levels in cases and controls (mmol/L), and fasting glucose difference and ratio between
cases and controls (mmol/L). Multivariate meta-regressions were also utilized to examine further the
covariates that had a significant influence on heterogeneity in univariate analysis. In addition, the
proportion of between-study variance explained by one or more covariates was estimated through the
adjusted R2 (RA2). Likewise, the percentage of residual variation due to heterogeneity which remains
unexplained by one or more covariates (Ir2) was obtained.
To assess the power of each study on the overall pooled estimates, sensitivity analysis was
performed using the leave-one-out method [36], where one study was excluded at a time, evaluating
the impact of removing each of the studies on the summary results and the between-study heterogeneity.
Furthermore, publication bias was investigated by visual inspection of funnel plots and quantitatively
assessed using Egger’s [37] and Begg’s [38] tests. All analyses were performed with STATA statistical
software, version 15.0. (STATA Corp., College Station, Texas, USA).
3. Results
The literature search strategy generated 12,136 publications, and 16 studies were finally selected
for this systematic review and meta-analysis of observational studies [4–7,10–12,14–19,39–41]. There
were no studies that were excluded for reasons of language. The details of the selection process and
the reasons for exclusion are shown in the flowchart (Figure 1). The quality of selected publications,
according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
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Statement [42], was high. The compliance percentages of the STROBE items were between 69 and 100%,
14 of the 16 selected studies above 80% [4–7,10–12,14–19,39,41]. The characteristics of the included
studies for meta-analyses are summarized in Tables 1–3.
3.1. Dietary Zinc Intake and T2DM
Seven prospective cohort studies [4–7,10,11] and one cross-sectional study [39] were included in
the meta-analysis of the association between dietary zinc intake and T2DM (Table 1). Five studies
were carried out in the western countries (USA, the Nurses’ Health Study (NHS) cohort [4], the
Multi-Ethnic Study of Atherosclerosis (MESA) cohort [10], and the Coronary Artery Risk Development
in Young Adults (CARDIA) cohort [11]; Australia, the Australian Longitudinal Study on Women’s
Health (ALSWH) cohort [5]; and Sweden, the Malmö Diet and Cancer Study (MDCS) cohort [6]),
and two in the eastern countries (India [39], and Japan, the Japan Collaborative Cohort (JACC) [7]).
This meta-analysis comprised 146,027 participants aged between 18 and 84 years, and of both genders,
belonging to different ethnic groups (Hispanic, Caucasian, African American, Chinese or South Asian,
among others), and areas of residence (rural or urban). During the follow-up of participants, between
4.8 years on average in the MESA cohort [10] and 24 years in the NHS cohort [4], 11,511 cases of T2DM
were detected (7.8%). The percentage of T2DM cases was highly variable between the studies, from
2.5% in the JACC study [7] to 14.1% in the Swedish MDCS cohort [6].
Dietary zinc intake was collected using validated food frequency questionnaires (VFFQs) [4,5,7,10],
validated diet history questionnaires (VDHQ) [6,11], or a 7-day dietary record [39]. The mean of dietary
zinc intake ranged from 5.6 ± 1.6 mg/day in urban women from India [39] to 16.7 mg/day in urban
subjects from the USA [11]. Ascertainment of T2DM was carried out through different criteria (fasting
plasma glucose (FPG) and/or oral glucose tolerance test (OGTT), and/or self-reported, and/or using
registries from different institutions, and/or use of antidiabetic drugs).
To evaluate the association between the dietary zinc intake and the T2DM, a meta-analysis was
conducted (Figure 2). The pooled effect size for T2DM comparing the highest versus lowest dietary
zinc intakes was 0.87 (95% CI: 0.78–0.98), with moderate to high heterogeneity (I2 = 64.5%, p = 0.003).
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Figure 2. Forest plot of pooled effect size of the highest versus lowest dietary zinc intake for T2DM.
Squares represent odds ratios (OR) for each study, and the size of the square is the study-specific
statistical weight. Horizontal lines indicate the 95% CI of each study. Diamond represents the combined
OR estimate with corresponding 95% CI.
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Table 1. Characteristics of studies reporting the association between dietary zinc intake and risk of type 2 diabetes.
Author, Year
(Study)
Location
(Area)
Study
Design
Follow-Up
(Years) Ethnicity Gender
Age (Years)
in Cases at
Baseline
(mean ± SD)
Age (Years) in
Controls at
Baseline
(mean ± SD)
Sample
Size
(T2DM)
T2DM
(%)
Ascertainment
of T2DM
Zinc
Assessment
Method
Zinc Intake
(mg/day) in
Cases
(mean ± SD)
Zinc Intake
(mg/day) in
Controls
(mean ± SD)
Effect Size
(95% CI)
Drake, 2017
(MDCS)
Sweden
(urban)
Prospective
cohort Median: 19 White
Men/
Women 58.0 ± 7.0 57.8 ± 7.7
26,132
(3676) 14.1
FPG ≥ 7.0
mmol/L (twice),
or registries
VDHQ 11.6 ± 3.6 11.1 ± 3.3 HR: 1.07(0.88–1.30)
Eshak, 2017
(JACC)
Japan (rural,
mostly)
Prospective
cohort 5 Japanese
Men/
Women Range: 40–65
16,160
(396) 2.5 Self-report VFFQ 7.3 ± 0.8
OR: 0.64
(0.54–1.00)
Park, 2016
(CARDIA)
USA
(urban)
Prospective
cohort 23
African
American,
Caucasian
Men/
Women Range: 18–30; 27.03 ± 3.61
3960
(418) 10.6
FPG ≥ 7.0
mmol/L, or 2-h
75-g OGTT ≥ 11.1
mmol/L, or
HbA1c ≥ 6.5%, or
drugs
VDHQ 16.7 HR: 1.27(0.81–2.01)
Vashum, 2013
(ALSWH)
Australia
(rural,
mostly)
Prospective
cohort 6 Australian Women Range: 45–50
8921
(333) 3.7 Self-report VFFQ 10.7
OR: 0.50
(0.32–0.77)
de Oliveira
Otto, 2012
(MESA)
USA
(urban)
Prospective
cohort Mean: 4.8
White,
Asian,
African
American,
Hispanic
Men/
Women Range: 45–84 61.8 ± 10.3
4982
(499) 10.0
FPG ≥ 6.99
mmol/L, or
self-reported, or
drugs
VFFQ Median (standard error) 8.3 (4.4) HR: 1.41(0.88–2.27)
Sun, 2009
(NHS)
USA
(urban)
Prospective
cohort 24 White Women Range: 33–60
82,297
(6030) 7.3 Self-report VFFQ N/A N/A
RR: 0.92
(0.84–1.00)
Singh, 1998
India (rural) Cross-sectional
study N/A South Asian
Men
25–64
894 (27) 3.0 FPG > 7.7
mmol/L, or 2-h
75-g OGTT > 11.1
mmol/L
7-day
dietary
record
8.8 ± 2.2 OR: 0.61(0.35–1.66)
Women 875 (24) 2.7 8.1 ± 2.1 OR: 0.58(0.44–1.15)
India
(urban)
Men 904 (63) 7.0 7.0 ± 2.0 OR: 0.90(0.82–0.98)
Women 902 (45) 5.0 5.6 ± 1.6 OR: 0.85(0.71–0.93)
Abbreviations: SD, Standard Deviation; T2DM, Type 2 Diabetes Mellitus; MDCS, Malmö Diet and Cancer Study; FPG, Fasting Plasma Glucose; VDHQ, Validated Diet History Questionnaire;
HR, Hazard Ratio; CI, Confidence Interval; JACC, Japan Collaborative Cohort; VFFQ, Validated Food Frequency Questionnaire; OR, Odds Ratio; CARDIA, Coronary Artery Risk
Development in Young Adults; OGTT, Oral Glucose Tolerance Test; HbA1c, Glycosylated Hemoglobin; ALSWH, Australian Longitudinal Study on Women’s Health; MESA, Multi-Ethnic
Study of Atherosclerosis; NHS, Nurses’ Health Study; N/A, Not Applicable or Not Available; RR, Relative Risk.
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Table 2. Characteristics of studies reporting the association between supplementary and total zinc intake and risk of type 2 diabetes.
Author, Year
(Study)
Location
(Area)
Study
Design
Follow-Up
(Years) Ethnicity Gender
Age (Years)
in Cases at
Baseline
(mean ± SD)
Age (Years) in
Controls at
Baseline
(mean ± SD)
Sample
Size
(T2DM)
T2DM
(%)
Ascertainment
of T2DM
Zinc
Assessment
Method
Zinc Intake
(mg/day) in
Cases
(mean ± SD)
Zinc Intake
(mg/day) in
Controls
(mean ± SD)
Effect Size
(95% CI)
Supplementary zinc intake
Drake, 2017
(MDCS)
Sweden
(urban)
Prospective
cohort Median: 19 White
Men/
Women 58.0 ± 7.0 57.8 ± 7.7
26,132
(3676) 14.1
FPG ≥ 7.0
mmol/L (twice),
or registries
VDHQ 12.3% user 17.7% user HR: 0.83(0.71–0.98)
Song, 2011
(NIH-AARP)
USA
(urban)
Prospective
cohort 10
White,
mostly
Men/
Women Range: 50–71
232,007
(14,130) 6.1 Self-report
Dietary
survey 12.5% user 5.7% user
OR: 1.05
(0.98–1.13)
Sun, 2009
(NHS)
USA (urban)
Prospective
cohort 24 White
Women
with low
dietary zinc
intake
Range: 33–60
27,432
(2002) 7.3 Self-report VFFQ 6.3% user in 1980–48.6% user in
2004
RR: 0.86
(0.74–0.99)
Prospective
cohort
Women
with high
dietary zinc
intake
27,432
(2002)
RR: 1.05
(0.92–1.19)
Total zinc intake
Drake, 2017
(MDCS)
Sweden
(urban)
Prospective
cohort Median: 19 White
Men/
Women 58.0 ± 7.0 57.8 ± 7.7
26,132
(3676) 14.1
FPG ≥ 7.0
mmol/L (twice),
or registries
VDHQ 12.9 ± 5.4 13.0 ± 6.2 HR: 1.05(0.88–1.25)
Sun, 2009
(NHS)
USA
(urban)
Prospective
cohort 24 White Women Range: 33–60 N/A
82,297
(6030) 7.3 Self-report VFFQ
Median range:
4.9–18.0 N/A
RR: 0.90
(0.82–0.99)
Abbreviations: SD, Standard Deviation; T2DM, Type 2 Diabetes Mellitus; MDCS, Malmö Diet and Cancer Study; FPG, Fasting Plasma Glucose; VDHQ, Validated Diet History Questionnaire;
HR, Hazard Ratio; NIH-AARP, National Institutes of Health-American Association of Retired Persons Diet and Health Study; OR, Odds Ratio; NHS, Nurses’ Health Study; N/A, Not
Applicable or Not Available; VFFQ, Validated Food Frequency Questionnaire; RR, Relative Risk.
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Table 3. Characteristics of studies reporting the association between serum/plasma and whole blood zinc concentration and risk of type 2 diabetes.
Author,
Year Location
Study
Design
Follow-Up
(Years) Ethnicity Gender
Age (Years) in
Cases at
Baseline
(mean ± SD)
Age (Years) in
Controls at
Baseline
(mean ± SD)
Sample
Size
(T2DM)
T2DM
(%)
Ascertainment of
T2DM
Zinc
Assessment
Method
Zinc Levels
(µg/dL) in
Diabetic Subjects
(mean ± SD)
Zinc Levels
(µg/dL) in
Controls
(mean ± SD)
Effect Size
(95% CI)
Serum/plasma zinc concentration
Yuan, 2018
(DFTJ)
China
(urban)
Nested
case-control 4.6 Chinese
Men/
Women 62.8 ± 7.2 62.9 ± 7.3
2078
(1039) N/A
FPG ≥ 7.0 mmoL/L,
or HbA1c ≥ 6.5%,
or self-reported, or
drugs
ICP-MS 169.6 ± 142.4 156.1 ± 126.5 OR: 1.09(0.81–1.48)
Li, 2017 China(urban) Cross-sectional N/A
Chinese
Han
Men/
Women
Range: 40–92,
mean: 66.3
Range: 40–92,
mean: 66.5
551
(122) N/A
RPG ≥ 11.1 mmol/L
and symptoms, 2-h
OGTT ≥ 11.1
mmol/L, or FPG ≥
7.0 mmol/L, or
HbA1c ≥ 6.5%
ICP-MS Median: 63.4 Median: 57.5 OR: 2.26(1.29–3.98)
Zhang, 2017
(REACTION)
China
(urban) Cross-sectional N/A Chinese
Men/
Women 57.7 ± 7.4 55.2 ± 7.9
1837
(510) N/A
Self-reported, or
FPG > 7.0 mmol/L,
or 2-h 75-g OGTT >
11.1 mmol/L
ICP-MS 109.0 ± 26.0 105.0 ± 25.0 OR: 1.79(1.13–2.84)
Yary, 2016
(KIHD)
Finland
(rural /
urban)
Prospective
cohort 20 N/A Men Range: 42–60
2220
(416) 18.7
Self-reported, or
FPG ≥ 7.0 mmol/L
or 2-h OGTT ≥ 11.1
mmol/L
AAS 95.0 ± 10.0 93.0 ± 12.0 HR: 1.39(1.04–1.85)
Skalnaya,
2016
Russia
(urban) Cross-sectional N/A N/A Women 55.8 ± 5.3 56.7 ± 6.1 128 (64) N/A HbA1c≥6.5% ICP-MS 96.0 ± 0.2 105.0 ± 0.2
OR: 0.33
(0.14–0.76)
Shan, 2014 China(urban) Cross-sectional N/A
Chinese
Han
Men/
Women 51.0 ± 10.8 42.5 ± 11.6
1578
(785) N/A WHO 1999 criteria ICP-MS 115.0 ± 45.0 172.5 ± 73.0
OR: 0.09
(0.06–0.13)
Whole blood zinc concentration
Simic, 2017
(HUNT3)
Norway
(rural,
mostly)
Cross-sectional N/A Caucasian,mostly
Men/
Women 65.4 ± 10.6 59.2 ± 12.2
876
(267) N/A Self-reported ICP-MS
Median: 764.3
Range (10–90%):
643.6–893.3
Median: 751.2
Range
(10–90%):
623.5–878.2
OR: 1.08
(0.59–1.97)
Hansen,
2017
(HUNT3)
Norway
(rural,
mostly)
Cross-sectional N/A Caucasian,mostly
Men/
Women 65.2 ± 10.3 61.4 ± 14.1
883
(128) N/A
FPG ≥ 7.0 mmol/L
and/or 2-h OGTT ≥
11.1 mmol/L
ICP-MS
Median: 799.0
Range (10–90%):
675.0–881.0
Median: 754.0
Range
(10–90%):
628.0–885.0
OR: 2.19
(1.05–4.59)
Abbreviations: SD, Standard Deviation; T2DM, Type 2 Diabetes Mellitus; DFTJ, Dongfeng–Tongji; FPG, Fasting Plasma Glucose; N/A, Not Applicable or Not Available; HbA1c, Glycosylated
Hemoglobin; ICP-MS, Inductively Coupled Plasma Mass Spectrometry; OR, Odds Ratio; RPG, Random Plasma Glucose; OGTT, Oral Glucose Tolerance Test; REACTION, Risk Evaluation
of cAncers in Chinese diabeTic Individuals: a lONgitudinal; KIHD, Kuopio IschaemicHeart Disease Risk Factor Study; AAS, Atomic Absorption Spectrophotometry; HR, Hazard Ratio;
WHO, World Health Organization; HUNT, North-TrØndelag Health.
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Through a stratified analysis based on the area of residence of participants, rural versus urban,
(Figure 3) we observed a higher and significant effect size in rural areas (OR = 0.59, 95% CI: 0.48–0.73),
and undetectable heterogeneity (I2 = 0.0%, p = 0.843), meanwhile in urban areas the effect became
non-significant (OR = 0.94, 95% CI: 0.86–1.02; I2 = 43.9%, p = 0.113). Subsequently, we used the
adjusted R2 to examine how much of the heterogeneity was accounted for by the area of residence
(Table 4), and we found that the heterogeneity was explained to a great extent (RA2 = 100.0%;
Ir2 = 17.8%). Interestingly, through a stratified analysis by the covariate “study design and area of
residence”, we observed that this protective effect of dietary zinc intake in rural areas was found in both
cross-sectional and prospective studies (Figure 4). In this analysis, results were statistically significant,
and heterogeneity was reduced (I2 = 0.0%, p > 0.050) for all subgroups, except for prospective studies
conducted in urban areas (OR = 1.04, 95% CI: 0.88–1.24; I2 = 50.7%, p = 0.107).
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ID
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0.92 (0.84, 1.00)
1.07 (0.88, 1.30)
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100.00
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13.58
5.29
17.00
Weight
19.54
5.02
20.53
4.60
8.62
79.47
%
  
1.25 2.3
Figure 3. Forest plot of pooled effect size of the highest vs. lowest dietary zinc intake for T2DM
according to area of residence (rural vs. urban). Squares represent ORs for each study, and the size of
the square is the study-specific statistical weight. Horizontal lines indicate the 95% CI of each study.
Diamond represents the combined OR estimate with corresponding 95% CI.
The corresponding adjusted R2 for this covariate was 90.47%. However, the covariate that showed
the greatest im act o the relationship studied was the percentage of T2DM, both as continuous and
categorized variable. Thus, the stratified analysis (Fig re 5) by this covariate categorized (<5/5–9.9/≥10)
revealed a significant protective effect of dietary zinc intake in those studies with <5% of T2DM
(OR = 0.59, 95% CI: 0.48–0.73; I2 = 0.0%, p = 0.843), and those between 5–9.9% (OR = 0.90, 95% CI:
0.85–0.95; I2 = 0.0%, p = 0.627), but not when it was higher than 10% (OR = 1.13, 95% CI: 0.96–1.34;
I2 = 0.0%, p = 0.499). It should be noted that the level of heterogeneity was reduced to 0.0% in all these
subgroups. The importance of this covariate in the assessed relationship was supported by the large
proportion of the between-st dy variance was explained (RA2 = 100.0%), as well as the undetectable
percentage of the residual variation that was attributable to the between-study heterogeneity, after
entering this covariate into a univariate meta-regression model (Ir2 = 0.0%).
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Table 4. Stratified meta-analyses and meta-regressions on the association between dietary zinc intake and risk of type 2 diabetes mellitus.
Subgroup Studies (n) Effect Size (95% CI)
Heterogeneity Meta-Regressions
I2 (%) p-Value Regression Coefficients (95% CI) Standard Error p-Value Tau2 I2 Residual (%) Adjusted R2 (%)
Geographic area
Western (1) 5 0.97 (0.77–1.22) 72.1% 0.006 −0.25 (−0.66; 0.17) 0.18 0.208 0.04 64.05% 6.68%Eastern (2) 5 0.80 (0.70–0.92) 49.3% 0.096
Geographic regions
Oceania (1) 1 0.50 (0.32–0.78) - -
0.22 (0.04–0.39) 0.08 0.022 0.02 50.38% 67.68%
Asia (2) 5 0.80 (0.70–0.92) 49.3% 0.096
America (3) 3 1.10 (0.82–1.47) 57.7% 0.094
Europe (4) 1 1.07 (0.88–1.30) - -
Area of residence
Rural (1) 4 0.59 (0.48–0.73) 0.0% 0.843 0.45 (0.16; 0.73) 0.13 0.007 0.00 17.82% 100.0%Urban (2) 6 0.94 (0.86–1.02) 43.9% 0.113
Gender
Men (1) 2 0.90 (0.82–0.98) 0.0% 0.331
0.14 (−0.17; 0.45) 0.13 0.330 0.06 67.67% −30.54%Women (2) 4 0.78 (0.65–0.95) 71.4% 0.015
Men/Women (3) 4 1.02 (0.73–1.42) 74.1% 0.009
Ethnicity
White (1) 3 0.86 (0.66–1.12) 79.4% 0.008
0.10 (−0.06; 0.26) 0.07 0.194 0.06 68.30% −17.63%South Asian (2) 4 0.86 (0.77–0.95) 28.5% 0.241Japanese (3) 1 0.64 (0.47–0.87) - -
Several ethnic groups (4) 2 1.34 (0.96–1.85) 0.0% 0.755
Study design
Prospective Cohort (1) 6 0.90 (0.73–1.12) 75.1% 0.001 −0.07 (−0.31; 0.16) 0.10 0.495 0.06 67.06% −33.29%Cross-sectional (2) 4 0.86 (0.77–0.95) 28.5% 0.241
Study design and area of residence
Prospective/Rural (1) 2 0.59 (0.46–0.76) 0.0% 0.367
0.18 (0.08; 0.29) 0.05 0.004 0.004 22.03% 90.47%
Cross-sectional/Rural (2) 2 0.58 (0.39–0.89) 0.0% 0.914
Cross-sectional/Urban (3) 2 0.88 (0.82–0.95) 0.0% 0.489
Prospective/Urban (4) 4 1.04 (0.88–1.24) 50.7% 0.107
Measure of association
Odds ratio (1) 5 0.75 (0.63–0.88) 63.2% 0.019
0.21 (0.05; 0.39) 0.07 0.016 0.02 49.76% 63.13%Relative risk (2) 1 0.92 (0.84–1.00) - -
Hazard ratio (3) 4 1.13 (0.96–1.34) 0.0% 0.499
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Table 4. Cont.
Subgroup Studies (n) Effect Size (95% CI)
Heterogeneity Meta-Regressions
I2 (%) p-Value Regression Coefficients (95% CI) Standard Error p-Value Tau2 I2 Residual (%) Adjusted R2 (%)
Sample size
<1000 4 0.86 (0.77–0.95) 28.5% 0.241
0.03 (−0.09; 0.14) 0.05 0.578 0.06 66.27% −29.83%1000–4999 2 1.34 (0.96–1.85) 0.0% 0.7555000–9999 2 0.59 (0.46–0.76) 0.0% 0.367
≥10,000 2 0.97 (0.84–1.11) 47.9% 0.166
Percentage of T2DM
<5% 4 0.59 (0.48–0.73) 0.0% 0.843
0.31 (0.15; 0.46) 0.07 0.002 0.00 0.00% 100.0%5–9.9% 3 0.90 (0.85–0.95) 0.0% 0.627
≥10% 3 1.13 (0.96–1.34) 0.0% 0.499
Zinc intake assessment method
VFFQ (1) 4 0.80 (0.57–1.12) 80.3% 0.002
−0.01 (−0.28; 0.26) 0.12 0.906 0.07 68.24% −40.61%VDHQ (2) 2 1.10 (0.92–1.31) 0.0% 0.497
7-day dietary record (3) 4 0.86 (0.77–0.95) 28.5% 0.241
Zinc quantiles adjusted for energy
Adjusted (1) 9 0.86 (0.76–0.96) 65.3% 0.003 0.42 (−0.40; 1.25) 0.36 0.271 0.04 65.34% 6.11%Not adjusted (2) 1 1.27 (0.81–2.00) - -
Ascertainment of T2DM
FPG/OGTT (1) 4 0.86 (0.77–0.95) 28.5% 0.241
0.19 (−0.05; 0.43) 0.10 0.112 0.04 62.01% 11.25%Self-reported (2) 3 0.70 (0.48–1.01) 82.6% 0.003
Several criteria (3) 3 1.13 (0.96–1.34) 0.0% 0.499
Diagnostic pattern
One diagnostic pattern 7 0.81 (0.72–0.91) 61.7% 0.016 0.41 (0.06; 0.77) 0.15 0.027 0.02 53.12% 51.60%Several diagnostic pattern 3 1.13 (0.96–1.34) 0.0% 0.499
Study quality
80–89 6 0.83 (0.71–0.97) 58.4% 0.035 −0.11 (−0.36; 0.58) 0.21 0.598 0.06 65.99% −23.10%≥90 4 0.92 (0.73–1.16) 74.0% 0.009
Abbreviations: CI, Confidence Interval; VDHQ, Validated Diet History Questionnaire; VFFQ, Validated Food Frequency Questionnaire; T2DM, Type 2 Diabetes Mellitus; FPG, Fasting
Plasma Glucose; OGTT, Oral Glucose Tolerance Test.
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Figure 4. Forest plot of pooled effect size of the highest vs. lowest dietary zinc intake for T2DM
according to study design and area of residence (prospective cohort studies in rural areas, cross-sectional
studies in rural areas, cross-sectional studies in urban areas, and prospective cohort studies in urban
areas). Squares represent ORs for each study, and the size of the square is the study-specific statistical
weight. Horizontal lines indicate the 95% CI of each study. Diamond represents the combined OR
estimate with corresponding 95% CI.
A multivariate meta-regression model adding the three covariates with a significantly higher
impact on the association, showed that only a “percentage of T2DM” continued being significant (0.23,
95% CI: 0.02, 0.45, p = 0.037). Once the fourth covariate was introduced, none remained significant.
When we analyzed the percentage of T2DM as a continuous variable, similar results were observed
(RA2 = 100.0%, Ir2 = 23.6%). A bubble plot was used to represent this covariate (Figure 6), and it
was found that, as the percentage of T2DM increased, the protective effect of a moderately high
dietary zinc intake was reduced in a relationship defined by the equation of the regression line:
(Ln(ORT2DM) = (−0.4217314) + 0.0437897 × (percentage of T2DM)).
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Figure 5. Forest plot of pooled effect size of the highest vs. lowest dietary zinc intake for T2DM
according to the percentage of T2DM (<5%/5–9.9%/≥10%). Squares represent ORs for each study, and
the size of the square is the study-specific statistical weight. Horizontal lines indicate the 95% CI of
each study. Diamond represents the combined OR estimate with corresponding 95% CI.
The effect size ranged between (OR = 0.84, 95% CI: 0.75–0.96) after excluding the study carried
out by Drake et al. [6], and (OR = 0.90, 95% CI: 0.81–0.99), after excluding the study conducted by
Vashum et al. [5]. However, the combined overall effect size remained on the verge of statistical
significance after removing the data obtained by Singh et al. [39] in urban Indian women (OR = 0.87,
95% CI: 0.76–1.00), or that of Eshak et al. [7] in Japanese subjects (OR = 0.90, 95% CI: 0.80–1.01). Finally,
for this meta-analysis, an overall symmetry of the funnel plots was observed by visual inspection
(Supplementary Materials Figure S1). This was confirmed by the Egger’s (p = 0.429) and Begg’s
(p = 0.721) tests, indicating the absence of publication bias.
3.2. Supplementary Zinc Intake and T2DM
Three studies of 313,003 individuals assessed the association between supplementary zinc intake
and T2DM (NHS cohort [4], Nat on In titutes of Health-American Association of Retired Persons
(NIH-AARP) Diet and Health Study [12], MDCS cohort [6]) (Table 2). The follow-up period of the e
prospective cohort studies ranged between 10 [12] to 24 years [4]. Participants were white (mostly)
women [4] r subjects of both genders [6,12], aged betw en 33 and 71 ye rs, and from urban areas.
In total, 17,806 patients with incident diabetes (betwe n 6.1 a 14.1%) were identified ccording to
different diagnostic criteria (self-reported [4,12], or through an FPG ≥ 7.0 mmol/L measured twice, and
institutional reg stries [6]).
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Figure 6. Bubble plot with a fitted eta-regression line of the relationship between the Ln(OR) and the
percentage of T2D . Circles are sized according to the precision of each estimate (the inverse of its
within-study variance).
Supplementary zinc intake was determined using different food intake instruments, such as
VFFQ [4], VDHQ [6], or dietary survey, including an FFQ and a short survey [12]. The percentage
of patients with incident diabetes supplemented with zinc was around 12.5% [6,12], meanwhile in
controls of non-incident diabetes, zinc supplementation ranged between 5.7% in the NIH-AARP Diet
and Health Study [12], to 17.7%, in the MDCS cohort [6]. The NHS cohort reported a large increase
in the proportion of women who were supplemented with zinc in 2004 (48.6%) compared with 1980
(6.3%) [4].
The association between supplementary zinc intake and the risk of T2DM was evaluated through
a meta-analysis stratified by whether the analysis had been done comparing zinc supplement users
versus non-users or comparing the highest versus lowest quantile of supplementary zinc intake, in
order not to introduce bias in the analysis (Figure 7). Results revealed a non-significant association
between zinc supplement users versus non-users and T2DM (OR = 0.94, 95% CI: 0.75–1.19; I2 = 85.4%,
p = 0.009), and between higher supplementary zinc intake versus lower and T2DM (OR = 0.95, 95% CI:
0.78–1.16; I2 = 75.3%, p = 0.044), and an elevated heterogeneity in both cases.
Publication bias was unlikely in this meta-analysis, according to Egger’s (p = 0.186), and Begg’s
(p = 0.089) tests (Figure S2).
3.3. Total Zinc Intake and T2DM
The fi al d ta set for the meta-analysis of total zinc intake and risk of T2DM included only
two large prospective cohort studies [4,6] (Table 2). Nevertheless, both studies comprised 108,429
individuals, 9706 patients with incident diabetes and 98,723 controls of non-incident diabetes. Incidence
of T2DM was 14.1% in the middle-aged Swedish cohort of urban men and women (MDCS) [6], and
7.3% in the American cohort of urban women (NHS) [4]. A VFFQ [4] and a VDHQ [6] were used to
determine the total zinc intake, that ranged from 4.9 to 18.0 mg/day in the NHS cohort [4], and around
12.9 ± 5.4 mg/day in controls of non-incident diabetes and 13.0 ± 6.2 mg/day in patients with incident
diabetes from the MDCS cohort [6].
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Figure 7. Forest plot of the pooled effect size of the highest versus lowest supplementary zinc intake for
T2DM according to the analysis (zinc supplement users/non-users versus quantiles of supplementary
zinc intake). Squares represent ORs for each study, and the size of the square is the study-specific
statistical weight. Horizontal lines indicate the 95% CI of each study. Diamond represents the combined
OR stimate with corresponding 95% CI.
After pooling data from both studies (Figure 8), we found that tot l zinc intake was not sig ificantly
associated with the incidence of T2DM (OR = 0.95, 95% CI: 0.82–1.11). There was moderate heterogeneity
between the studies (I2 = 56.5%, p = 0.129). Moreover, no evidence of publication bias was found
(p = 1.000) (Supplementary Materials Figure S3).
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Figure 8. Forest plot of pooled effect size of the highest vs. lowest total zinc intake for T2DM.
Squares represent ORs for each study, and the size of the square is the study-specific statistical weight.
Horizontal lines indicate the 95% CI of each study. Diamond represents the combined OR estimate
with corresponding 95% CI.
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3.4. Whole Blood Zinc Concentration and T2DM
Only two cross-sectional studies carried out within the third survey of the population-based
Nord-Trøndelag Health Study (HUNT3 Survey) were identified to assess the relationship between
concentration of zinc in whole blood and T2DM [18,19]. The fact that both studies shared part of the
same study sample prevented the execution of a meta-analysis to obtain a pooled result. Nevertheless, a
qualitative summary was conducted to present the findings of these two studies (Table 3). Participants
in both studies were men and women, mainly Caucasian, and aged around 61.5 ± 8.7 years old,
who lived mainly in rural areas from Norway. The main difference between these two studies was
the sampling strategy. Hansen et al. [18] selected 876 subjects at high risk for T2DM, but without
previously known diabetes. In this study, 128 previously undiagnosed cases of T2DM, were detected
by screening [18]. In contrast, Simic et al. [19] included 883 subjects, of which 267 had self-reported
T2DM, i.e., they were patients in a more advanced stage of the disease. Curiously, while Hansen et
al. [18] found a significant and positive association between a higher whole blood zinc concentration
and the onset of T2DM (OR = 2.19, 95% CI: 1.05–4.59), Simic et al. [19] did not observe any significant
relationship (OR = 1.08, 95% CI: 0.59–1.97). Differences in concentrations of zinc in whole blood
between cases and controls, measured in both studies through inductively coupled plasma mass
spectrometry (ICP-MS), were more evident in the study conducted by Hansen et al. [18] (median in
cases: 799.0 µg/dL; median in controls: 754.0 µg/dL) compared to the one carried out by Simic et al. [19]
(median in cases: 764.3 µg/dL; median in controls: 751.2 µg/dL). It is worth noting that the median
whole blood zinc concentration in the control subjects in both studies was very similar, but not in those
of the diabetic subjects.
3.5. Serum/Plasma Zinc Concentration and T2DM
Six observational studies (one prospective cohort study [14], one nested case-control study [15],
and four cross-sectional studies [16,17,40,41]) were included in the meta-analysis of serum/plasma
zinc concentration and T2DM (Table 3). Four studies were carried out on Chinese urban men and
women between the ages of 40 and 90 years [15,16,40,41], one in Russian women with an average age
of 56.3 ± 5.7 years [17], and one in Finnish men aged between 42 and 60 years [14]. The total number of
cases of T2DM was 2936, among 8392 participants. The period of follow-up was between 4.6 years in the
nested case control within the Dongfeng–Tongji (DFTJ) cohort [15], and 20 years in the KIHD study [14].
Serum/plasma zinc concentration was determined mainly by ICP-MS [15–17,40,41], meanwhile the
KIHD used atomic absorption spectrophotometry (AAS) [14]. The levels of serum/plasma zinc in
controls ranged from a median of 57.5 µg/dL to a mean of 172.5 ± 73.0 µg/dL; and in cases from a
median of 63.4 µg/dL to a mean of 169.6 ± 142.4 µg/dL.
The combined effect size of T2DM for the highest versus lowest quantile of serum/plasma zinc
concentration was 0.76 (95% CI: 0.29–2.01). However, a high level of heterogeneity was found (I2 = 97.1%,
p < 0.001). Sensitivity analysis omitting one study at a time and calculating the heterogeneity for the
remainder of the studies showed that the study conducted by Shan et al. [16] substantially influenced
the overall heterogeneity, resulting in a reduction around 31% of this when it was excluded. In addition,
the elimination of this study and the one carried out by Skalnaya et al. [17], decreased the level of
heterogeneity by 44.5%, showing their impact on results (OR = 1.47, 95% CI: 1.11–1.95; I2 = 53.9%,
p= 0.090). Nevertheless, the exclusion of any other study had a negligible effect on heterogeneity. When
performing stratified analysis for “sample base” (Figure 9), a significant and positive association was
found in the subgroup of “population or community-based studies” (OR = 1.64, 95% CI: 1.25–2.14), and
a low heterogeneity (I2 > 22.5%, p = 0.275). On the other hand, “non-population or community-based
studies” showed a very high level of heterogeneity (I2 > 98.0%, p < 0.001). Likewise, when it was
stratified by the covariate “group with higher zinc levels”, a relationship between serum/plasma zinc
levels and T2DM (OR = 1.47, 95% CI: 1.11–1.95; I2 = 53.9%, p = 0.090) was observed in the subgroup
of studies with higher zinc levels in the case group compared to controls (Table S3). Meanwhile, a
significant negative relationship was found in the subgroup in which controls had higher serum/plasma
Nutrients 2019, 11, 1027 18 of 26
concentration (OR = 0.16, 95% CI: 0.05–0.54), but with a high heterogeneity (I2 = 86.4%, p = 0.007).
Finally, the difference in mean serum/plasma zinc concentration between cases and controls, as well its
ratio, also explained, to a large extent, the heterogeneity observed (RA2 = 85.2%, for mean difference;
and RA2 = 92.6%, for mean ratio), as expected.
Although the funnel plot showed some degree of asymmetry (Figure S3), we did not detect any
risk of publication bias according to the Egger’s (p = 0.815) or Begg’s tests (p = 0.707).
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Figure 9. Forest plot of pooled effect size of the highest vs. lowest serum/plasma zinc
concentration for T2DM according to the sample base (population/com unity-based studies vs.
non-population/community-based studies). Squares represent ORs for each study, and the size of
the square is the study-specific statistical weight. Horizontal lines indicate the 95% CI of each study.
Diamond represents the combined OR estimate with corresponding 95% CI.
4. Discussion
This systematic review and meta-analysis of observational studies found an inverse association
between dietary zinc intake and T2DM. This could suggest a potential beneficial role of zinc from diet
to prevent the risk of this disease. In additi n, the relationship seem d to be more evident in rural
areas, and when the proportion of T2DM cases in the p pulation was low or derate. Conversely,
a non-significant association between tot l or supplementary zinc intake and T2DM was obs rved,
although d ta are limited. Whol blood zinc concentration could be directly related to T2DM only at an
early phase of the diab tes disease, as suggested by results fr m the sam cohort stu y. This hypothesis
could not be xamin d for serum/pl sma zinc concentration. Nevertheless, a positive relationship was
found between this biomarker of zinc status and T2DM i population-based studies.
Our results s ggest that a diet moderately elevated in zinc could help to prevent the d velopm nt
of T2DM. We tried to determine th cut- ff point or range of dietary zinc intake with a protective
ff ct agai st type 2 diab tes mellitus (T2DM); owever, data were imprecise, heterogeneous, and not
reported in all the studies. Despite these limitations in the data of the sel cted studies, it was notable
that when the lowest quantiles (reference) did not reach the dietary reference intakes (DRI) according to
the Institute Of Medicine (IOM) for adult men (11 mg/day) and women (8 mg/day) [43], those quantiles
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of dietary zinc intake that reached or moderately exceeded the DRI showed a protective effect, even in
the intermediate quantiles [4,5]. Furthermore, when the highest quantiles of dietary zinc intake did not
reach the DRI, no significant association was observed [10]. Interestingly, when the lowest quantiles of
dietary zinc intake reached the DRI, the highest quantiles (>23.34 mg/day) did not show a protective
effect on T2DM, and could even have a harmful impact on the risk of T2DM as observed in a model
not fully adjusted [11]. These data seem to suggest that a dietary zinc intake within or slightly above
the DRI could have a protective role on the risk of T2DM, but not when intake is very high. Consistent
with our findings, several observational studies have shown a protective effect of a moderately high
dietary zinc intake on cardiometabolic conditions, such as metabolic syndrome [44,45] and gestational
hyperglycemia [46], and mortality by cardiovascular disease [47] and all causes [48]. Conversely, other
studies have found no significant [10,49], or even direct associations [50,51] between dietary zinc intake
and some of these cardiometabolic events. The first systematic review of prospective cohort studies on
the association between zinc status, including dietary zinc intake, and risk of cardiovascular disease and
T2DM [13] revealed a limited number of studies on this topic, as well as the inconsistence of their results.
As the authors themselves suggested, the effect of confounding factors may have played an important
role in the observed findings. In our meta-analysis we have evaluated a large number of confounding
factors in order to identify and quantify those that could impact on the relationship between dietary
zinc intake and T2DM. Gender is one of the confounding factors most reported in the above mentioned
studies on the relationship between dietary zinc intake and metabolic syndrome [44,45], cardiovascular
disease [13], and mortality [47]. Our results showed a similar significant inverse association between
dietary zinc intake and T2DM in both men and women, suggesting that gender does not seem to have
a relevant role in this relationship.
Interestingly, we observed that the covariate “area of residence” of participants (rural versus
urban) had a key effect on our findings. While a strong inverse association was observed in studies
conducted on participants living in rural areas, a null relationship was observed in those studies
carried out on urban subjects (Figure 3). Interestingly, when we addressed these findings also taking
into account the design of the studies, we observed a 41% reduction in the risk of T2DM in both
cross-sectional and prospective studies conducted in rural areas (Figure 4). Conversely, the effect size
was reduced to 12% in cross-sectional studies performed in urban areas, and in prospective cohort
studies, the association was not significant. These observations support the hypothesis that living in
urban areas may counteract the beneficial effect of an elevated dietary zinc intake on risk of T2DM.
Accumulating evidence strongly suggests that the change from rural to urban environments may have
a marked impact on lifestyle [52,53], resulting in the increase of certain risk factors, such as unhealthy
diets, sedentary behavior, and smoking, among others, that account for a large contribution to global
burden of major disease [54,55]. Thus, it has been revealed that T2DM risk factors are more common
in urban than in rural areas [56]. The greater exposure to risk factors in urban environments could
explain the small or null protective effect of the intake of zinc from diet against the risk of T2DM.
Indeed, it is known that there is higher prevalence of T2DM in urban compared to rural areas [2,56].
According to the International Diabetes Federation (IDF) Diabetes ATLAS edition 2017, the global
prevalence of diabetes in urban areas was 10.2%, i.e., 279.2 million people aged between 20–79 years,
meanwhile in rural areas was notably lower, 6.9% (145.7 million) [2]. In addition, the number of people
living with diabetes in urban areas is expected to increase to 472.6 million in 2045, due mainly to global
urbanization [2].
It is interesting that the covariate which had the greatest impact on the association between dietary
zinc intake and T2DM was the proportion of T2DM cases identified in each study, both as a continuous
and categorized variable. When we conducted a meta-regression introducing the percentage of T2DM
as a continuous variable, we found that for each percentage point that increased this covariate, the
protective effect of a moderately high dietary zinc intake, relative to the DRI, against T2DM decreased
0.04 (95% CI: 0.01, 0.07, p = 0.010). Through a meta-regression equation represented in a bubble
plot, we observed that when the proportion of T2DM subjects reached 10%, the protective effect
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from dietary zinc intake was nullified (Figure 6). Consistently, the three studies with a proportion
of T2DM subjects of 10% or more, did not find a significant association between dietary zinc intake
and T2DM [6,10,11]. In addition, stratified analysis based on the percentage of T2DM in each study
(<5%, 5%–9.9%, and ≥10%) showed an undetectable heterogeneity in all the three subgroups (I2 = 0.0%,
p > 0.100), which provides high reliability to the results. Furthermore, a significant inverse association
was found between intake of zinc from diet and T2DM when the percentage of T2DM was lower than
10%, and with the highest effect size when that was less than 5% (Figure 5). It should be noted that
the studies with less proportion of T2DM subjects (<5%) were those carried out in rural areas, while
those with the highest percentage of diabetics (5%–9.9%, and ≥10%) were the studies conducted in
urban areas. In addition, among studies of urban areas, those with a moderate proportion of T2DM
(5%–9.9%) retained a significant association between dietary zinc intake and T2DM, although it was
more attenuated than those in rural areas. Nevertheless, the studies with higher percentage of T2DM
did not find any significant relationship (Figure 5). These results suggest that in rural areas, with
less T2DM risk factors, and consequently, less T2DM prevalence, the association between dietary
zinc intake and T2DM is significant and the effect size is strong; meanwhile, in urban areas, with a
greater exposure to T2DM risk factors and a higher T2DM prevalence, the association is still significant
but with a low effect size when T2DM prevalence is moderate, and not significant when the T2DM
prevalence is high.
Only two studies have evaluated the effect of a high total zinc intake on the risk of T2DM [4,6],
and the overall pooled estimates showed no significant association (Figure 8). The NHS cohort showed
a moderate protective effect of total zinc intake, while the MDCS cohort did not find a relationship.
Consistent with results from the meta-analysis of the dietary zinc intake, the NHS cohort [4] had a
moderate proportion of T2DM (7.3%), meanwhile the MDCS cohort [6] presented the highest percentage
of T2DM of all included studies in this systematic review (14.1%). This supports the hypothesis
previously raised regarding the impact of the T2DM prevalence on the association between zinc intake
and risk of T2DM.
Although, there is currently some evidence of the beneficial effect of zinc supplementation on
glycemic control in T2DM patients [9,57], scarce studies support the use of zinc supplements in the
prevention of this disease [8]. A recent clinical trial based on zinc supplementation has found a reduction
in the progression to T2DM in prediabetic subjects, in addition to an improvement in blood glucose and
insulin levels, insulin resistance, and β–cell function [9]. Observational studies that have assessed the
association between supplementary zinc intake and risk of T2DM are also scarce [4,6,12]. The overall
pooled estimates did not show any significant relationship, neither comparing zinc supplement users
versus non-users, nor comparing the highest versus lowest quantile of supplementary zinc intake
(Figure 7). Those studies that compared zinc supplement users versus non-users against the risk
of T2DM, failed to differentiate between participants who obtained zinc from multivitamin/mineral
supplements from those taking individual zinc supplements [6,12]. Thus, a synergistic effect or an
interaction between minerals and vitamins supplemented, along with zinc, could have affected the
relationship between supplementary zinc intake and the risk of T2DM. Interestingly, the NHS cohort
reported a significant inverse association in participants with low dietary zinc intake, but not in those
with high dietary zinc intake [4]. In addition, dietary zinc intake was more strongly associated with a
lower risk of T2DM among those participants with low zinc intakes from supplements. This seems
to suggest that only when the zinc intake is insufficient, zinc supplementation may have benefits.
However, when dietary intake is adequate, additional zinc intake from supplementation may not
confer further benefit.
To the best of our knowledge, only two cross-sectional studies, conducted within the same
population-based HUNT3 study, have evaluated the association between whole blood zinc concentration
and T2DM [18,19]. However, the results were dissimilar, likely due to characteristics of participants
selected during the sampling. Interestingly, Hansen et al. [18] reported a significant and positive
association between whole blood zinc concentration and T2DM, in previously undiagnosed diabetic
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patients and control subjects [18]. Meanwhile, Simic et al. [19], did not find a significant relationship in
previously diagnosed T2DM patients and control subjects. These results seem to suggest that when
T2DM is in the early stages, i.e., newly diagnosed, zinc levels are more elevated than non-diabetic
subjects, and progressively they are reduced as the disease progresses, which is consistent with our
previous systematic review and meta-analysis [20]. That meta-analysis which aimed to compare whole
blood zinc concentration between T2DM patients and non-diabetic subjects, showed that duration
of T2DM had a relevant influence on concentration of zinc in whole blood [20]. In addition, we
found a lower whole blood zinc concentration in T2DM patients; however, this group had, at least,
10.2 ± 8.6 years of duration of diabetes, and differences between cases and controls in that study were
not observed [58], in concordance with the study of Simic et al. [19], among previously diagnosed
T2DM participants [19].
Since the use of whole blood zinc concentration may be not representative of the total zinc
body burden [56], we also assessed the association between zinc and T2DM, through a more reliable
biomarker of zinc status, the serum/plasma zinc concentration [59]. We wanted to contrast the
hypothesis regarding the impact of the T2DM phases on serum/plasma zinc concentration; however,
data were limited to carry out that analysis. Only six studies evaluated this relationship, and results were
inconsistent [14–17,40,41], which was highlighted by high heterogeneity observed after the results were
combined. Two of the included studies were responsible for 44.5% of the heterogeneity detected [16,17].
After both studies were excluded, the combined result was more reliable (OR = 1.47, 95% CI: 1.11–1.95;
I2 = 53.9%, p = 0.090). Curiously, these two studies, together with the third that contributed more
to the global heterogeneity, were conducted on non-population or community-based studies, i.e.,
hospital-based settings [16], retired employees of a motor company [15] and postmenopausal women on
a voluntary basis [17], so the results could not be extrapolated to the general population. However, the
other three studies were carried out on population [14] or community-based [40,41] studies. Stratified
analysis according to the “sample base” (Figure 9) showed a high heterogeneity in the “non-population
or community-based studies” group (I2 = 98.0%, p < 0.001), and a low heterogeneity in the “population
or community-based studies” group (I2 = 22.5%, p = 0.275). The pooled estimates for this last subgroup
revealed a direct and significant association between serum/plasma zinc concentration and T2DM
(OR = 1.64, 95% CI: 1.25–2.14). This finding is not consistent with a previous meta-analysis that
compared serum/plasma zinc levels between T2DM patients and healthy controls [60]. Results of this
previous meta-analysis showed significantly lower serum/plasma zinc concentration in diabetic subjects
compared to healthy controls, but with high heterogeneity. The high heterogeneity suggests that
results were influenced by confounding factors, but its source was not analyzed in that meta-analysis.
Finally, a recent cross-sectional study reported that urinary zinc levels were positively associated with
T2DM [61]. These findings suggest this is a response mechanism against zinc excess in serum/plasma in
diabetic patients, and it seems to be in concordance with the direct relationship between serum/plasma
and T2DM that we observed in our meta-analysis.
Several limitations in the present systematic review and meta-analysis should be considered.
First, the number of results and studies included in meta-analyses was small, and stratified analyses
might have insufficient power to identify potential confounding factors, as well as to detect potential
sources of heterogeneity. To correct this weakness, random effects meta-regressions were carried
out. Furthermore, our findings were likely to be influenced by imprecise measurement of zinc intake.
However, VFFQ and VDHQ were used to assess dietary, supplementary, and/or total zinc intake, in all
but two studies. In addition, differences in diagnostic criteria for the ascertainment of T2DM over the
years could have introduced misclassification bias and could affect results. Finally, meta-analyses were
based on observational studies, which are prone to confounding and reverse causation. Nevertheless,
for meta-analyses of dietary, supplementary and/or total zinc intake, all but one of the included studies
were prospective cohort studies, which allows stronger inferences than cross-sectional studies [62].
Our study has also several strengths. Firstly, the comprehensive and robust search strategy within
the framework of the EURRECA Network of Excellence was designed to avoid the loss of relevant
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studies. Moreover, there were no studies that were excluded for reasons of language, avoiding language
bias. In addition, standard tests and visual inspection of funnel plots did not show any evidence for
risk of publication bias in any meta-analysis. Furthermore, included studies were of high quality,
according to the STROBE Statement [42]. The meta-analyses included 575,851 subjects, had a wide
geographical spread, and a diverse ethnicity, giving more validity to the results. Finally, heterogeneity
was low or moderate in most of the meta-analyses, which also contributes to the study validity.
The important role of zinc on carbohydrate metabolism via several mechanisms is well established,
and this could explain the protective effect of dietary zinc intake on risk of T2DM observed in our
meta-analysis. Zinc is involved in synthesis, storage, crystallization, and secretion, as well as the
action of insulin and translocation of insulin into the cells [21–24]. In addition, zinc seems to play
a role in insulin sensitivity through the activation of the phosphoinositol-3-kinase/protein kinase B
cascade [25]. It has also a role insulin–mimetic, being involved in the regulation process of glucose
homeostasis [26]. Moreover, zinc may participate in the suppression of proinflammatory cytokines,
such as interleukin-1β [27] and nuclear factor kβ [28], avoiding β-cells’ death and protecting insulin.
The underlying mechanism whereby higher serum/plasma and/or whole blood zinc concentration could
be related to T2DM is unclear. However, strong evidence supports disturbances in zinc homeostasis
associated with T2DM, that could not be linked to zinc status [63,64]. In recent years, it has been
proposed that the cellular zinc transport system may play a key role in the pathophysiology of
T2DM [65,66]. Thus, differences between diabetic patients and healthy controls in gene expressions for
most zinc transporters has been observed [63]. This zinc dyshomeostasis may be caused in the early
stages of T2DM, as observed in a trend of increased serum zinc levels from healthy to prediabetic and
diabetic postmenopausal women [67].
5. Conclusions
Findings from this systematic review and meta-analysis revealed a potential protective effect of a
moderately high dietary zinc intake, related to the DRI, on the risk of T2DM. The relationship seems to
be stronger and more evident in rural compared to urban areas. In addition, T2DM prevalence may be
also a confounding factor for this association, being stronger when the prevalence is low, weak when it
is moderate, and disappearing with a high prevalence. Conversely, no associations were observed
between total or supplementary zinc intake and T2DM. However, more data are required to explore
this relationship more fully.
In addition, an elevated serum/plasma zinc concentration is associated with an increased risk of
T2DM in the general population. Meanwhile, high whole blood zinc concentration could be associated
with T2DM, likely only at an early phase of the diabetes disease. Additional studies are required to
confirm these results, and determine the role of serum/plasma and whole blood zinc concentration in
the pathophysiology of T2DM.
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